Openbookopenbook
Equity
BioRegenx, Inc.(BRGX)
USD --+0.00%
Reward59Moderate
Risk65Medium-High
📊75%Data
Thin -83% profit margin · Revenue down 16% YoY
BRGX
+0.0 · +0.00%
USD · PINK
BioRegenx, Inc. | Healthcare
Profitless Growth
Market Cap:8.72M
ℹ️
Reward Rating
59
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
65
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BRGX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is BioRegenx, Inc.?

develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally.

BRGX · Verdict

Solid reward · elevated risk

BRGX stands out on growth and volatility, but watch the balance sheet signal.

Based on 88% data coverage

BRGX · Verdict

What’s working & what to watch

Strengths 2

  • Growth75/100

    Rev +253.0% CAGR · earnings +170.1%

  • Volatility75/100

    Above average

Watchouts 3

  • Balance sheet7/100

    Current ratio 0.06

  • Cash flow40/100

    2% free-cash-flow margin

  • Profitability44/100

    -83% net margin · -382% ROE

Model-based scoring. For information only — not financial advice.

What is BioRegenx, Inc.?

develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally. The company offers Endocalyx Pro, a dietary supplement targeting microvascular capillary health and a range of other supplements under the MyBodyRx brand name; GlycoCheck software; and other health and wellness devices, such as pulsed electro-magnetic field devices, as well as StimaWELL and ReLounge, an electronic muscle stimulation therapy device; and markets hydrogen water products. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.72M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (59)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap8.72M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.03
52 Week Low0.0075
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding969M
No. of Employees6
IndustryHealth Information Services
ExchangePINK
Beta-2.874
CurrencyUSD
Websitewww.bioregenx.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.